Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Mar;40(3):691–695. doi: 10.1128/aac.40.3.691

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

A S Benko 1, D M Cappelletty 1, J A Kruse 1, M J Rybak 1
PMCID: PMC163181  PMID: 8851594

Abstract

The pharmacodynamics and pharmacokinetics of ceftazidime administered by continuous infusion and intermittent bolus over a 4-day period were compared. We conducted a prospective, randomized, crossover study of 12 critically ill patients with suspected gram-negative infections. The patients were randomized to receive ceftazidime either as a 2-g intravenous (i.v.) loading dose followed by a 3-g continuous infusion (CI) over 24 h or as 2 g i.v. every 8 h (q8h), each for 2 days. After 2 days, the patients were crossed over and received the opposite regimen. Each regimen also included tobramycin (4 to 7 mg/kg of body weight, given i.v. q24h). Eighteen blood samples were drawn on study days 2 and 4 to evaluate the pharmacokinetics of ceftazidime and its pharmacodynamics against a clinical isolate of Pseudomonas aeruginosa (R288). The patient demographics (means +/- standard deviations) were as follows: age, 57 +/- 12 years; sex, nine males and three females; APACHE II score, 15 +/- 3; diagnosis, 9 of 12 patients with pneumonia. The mean pharmacokinetic parameters for ceftazidime given as an intermittent bolus (IB) (means +/- standard deviations) were as follows: maximum concentration of drug in serum, 124.4 +/- 52.6 micrograms/ml; minimum concentration in serum, 25.0 +/- 17.5 micrograms/ml; elimination constant, 0.268 +/- 0.205 h-1; half-life, 3.48 +/- 1.61 h; and volume of distribution, 18.9 +/- 9.0 liters. The steady-state ceftazidime concentration for CI was 29.7 +/- 17.4 micrograms/ml, which was not significantly different from the targeted concentrations. The range of mean steady-state ceftazidime concentrations for the 12 patients was 10.6 to 62.4 micrograms/ml. Tobramycin peak concentrations ranged between 7 and 20 micrograms/ml. As expected, the area under the curve for the 2-g q8h regimen was larger than that for CI (P = 0.003). For IB and CI, the times that the serum drug concentration was greater than the MIC were 92 and 100%, respectively, for each regimen against the P. aeruginosa clinical isolate. The 24-h bactericidal titers in serum, at which the tobramycin concentrations were < 1.0 microgram/ml in all patients, were the same for CI and IB (1:4). In the presence of tobramycin, the area under the bactericidal titer-time curve (AUBC) was significantly greater for IB than CI (P = 0.001). After tobramycin was removed from the serum, no significant difference existed between the AUBCs for CI and IB. We conclude that CI of ceftazidime utilizing one-half the IB daily dose was equivalent to the IB treatment as judged by pharmacodynamic analysis of critically ill patients with suspected gram-negative infections. No evaluation comparing the clinical efficacies of these two dosage regimens was performed.

Full Text

The Full Text of this article is available as a PDF (211.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker-Woudenberg I. A., van den Berg J. C., Fontijne P., Michel M. F. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol. 1984 Apr;3(2):131–135. doi: 10.1007/BF02014330. [DOI] [PubMed] [Google Scholar]
  2. Barriere S. L., Ely E., Kapusnik J. E., Gambertoglio J. G. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985 Jul;16(1):49–59. doi: 10.1093/jac/16.1.49. [DOI] [PubMed] [Google Scholar]
  3. Bodey G. P., Ketchel S. J., Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 1979 Oct;67(4):608–616. doi: 10.1016/0002-9343(79)90242-0. [DOI] [PubMed] [Google Scholar]
  4. Bustamante C. I., Drusano G. L., Tatem B. A., Standiford H. C. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Nov;26(5):678–682. doi: 10.1128/aac.26.5.678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cappelletty D. M., Kang S. L., Palmer S. M., Rybak M. J. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995 Aug;39(8):1797–1801. doi: 10.1128/aac.39.8.1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Craig W. A., Ebert S. C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother. 1992 Dec;36(12):2577–2583. doi: 10.1128/aac.36.12.2577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Craig W. A., Ebert S. C. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63–70. [PubMed] [Google Scholar]
  9. Daenen S., de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet. 1988 Apr 23;1(8591):937–937. doi: 10.1016/s0140-6736(88)91741-2. [DOI] [PubMed] [Google Scholar]
  10. David T. J., Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989 Jun 24;1(8652):1454–1455. doi: 10.1016/s0140-6736(89)90164-5. [DOI] [PubMed] [Google Scholar]
  11. Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hatano K., Wakai Y., Watanabe Y., Mine Y. Simulation of human plasma levels of beta-lactams in mice by multiple dosing and the relationship between the therapeutic efficacy and pharmacodynamic parameters. Chemotherapy. 1994 Jan-Feb;40(1):1–7. doi: 10.1159/000239162. [DOI] [PubMed] [Google Scholar]
  13. Kuzemko J., Crawford C. Continuous infusion of ceftazidime in cystic fibrosis. Lancet. 1989 Aug 12;2(8659):385–385. doi: 10.1016/s0140-6736(89)90561-8. [DOI] [PubMed] [Google Scholar]
  14. Lagast H., Meunier-Carpentier F., Klastersky J. Treatment of gram-negative bacillary septicemia with cefoperazone. Eur J Clin Microbiol. 1983 Dec;2(6):554–558. doi: 10.1007/BF02016564. [DOI] [PubMed] [Google Scholar]
  15. Lavoie G. Y., Bergeron M. G. Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae. Antimicrob Agents Chemother. 1985 Sep;28(3):404–412. doi: 10.1128/aac.28.3.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. LeBel M., Barbeau G., Vallee F., Bergeron M. G. Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother. 1985 Nov;28(5):713–715. doi: 10.1128/aac.28.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  18. Mouton J. W., Horrevorts A. M., Mulder P. G., Prens E. P., Michel M. F. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother. 1990 Dec;34(12):2307–2311. doi: 10.1128/aac.34.12.2307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mouton J. W., den Hollander J. G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994 May;38(5):931–936. doi: 10.1128/aac.38.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nicolau D. P., Nightingale C. H., Banevicius M. A., Fu Q., Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996 Jan;40(1):61–64. doi: 10.1128/aac.40.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
  22. Roosendaal R., Bakker-Woudenberg I. A., van den Berg J. C., Michel M. F. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis. 1985 Aug;152(2):373–378. doi: 10.1093/infdis/152.2.373. [DOI] [PubMed] [Google Scholar]
  23. Roosendaal R., Bakker-Woudenberg I. A., van den Berghe-van Raffe M., Michel M. F. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother. 1986 Sep;30(3):403–408. doi: 10.1128/aac.30.3.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Smith I. L., Schentag J. J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci. 1984 Feb;73(2):281–282. doi: 10.1002/jps.2600730239. [DOI] [PubMed] [Google Scholar]
  25. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES